ImmunityBio (IBRX.US): The 2024 Q1 financial report achieved revenue of 40,000 US dollars, the previous value was 360,000 US dollars, the expected value was 20,000 US dollars; earnings per share were -0.20 US dollars, the previous value was -0.27 dollars, and the expected value was -0.16 US dollars.
ImmunityBio(IBRX.US)：2024年Q1财报实现营收4万美元，前值为36万美元，预期值为2万美元；每股收益为-0.20美元，前值为-0.27美元，预期值为-0.16美元。
ImmunityBio (IBRX.US): The 2024 Q1 financial report achieved revenue of 40,000 US dollars, the previous value was 360,000 US dollars, the expected value was 20,000 US dollars; earnings per share were -0.20 US dollars, the previous value was -0.27 dollars,
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.